[en] Incomplete regression of a lymphomatous mass after chemotherapy and/or radiotherapy constitutes a major problem in the treatment of lymphoma. In patients with persisting tumor, it could be reasonable to use salvage therapy and possibly hematopoietic stem cell transplantation at the time of minimal disease rather than at the time of clinically overt relapse. The authors reviewed the most appropriate imaging techniques for the assessment of response to treatment. The limitations of CT and MRI for predicting the nature of residual masses are well known. 67Ga scintigraphy has become a standard procedure for the posttreatment evaluation of patients with lymphoma, but it appears that 18F-FDG PET may be a more effective method. Personal experience in the field of PET scan is reported. Although PET should be considered the noninvasive imaging modality of choice, a histological confirmation of residual disease is always necessary before starting salvage therapy. 18F-fluorodeoxyglucose is not a tumor specific radiotracer.
Disciplines :
Hematology
Author, co-author :
Warland, V.
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Hustinx, Roland ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire
Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Silvestre, R. M.
Fassotte, Marie-France ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Foidart, Jacqueline ; Centre Hospitalier Universitaire de Liège - CHU > Médecine nucléaire
Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
French
Title :
Comment etablir le bilan de fin de traitement des patients atteints de lymphomes non-hodgkiniens (LNH) de malignite intermediaire ou elevee?
Alternative titles :
[en] End of treatment evaluation in patients with aggressive non-Hodgkin's lymphoma
Publication date :
2002
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Canellos GP. - Residual mass in lymphoma may not be residual disease. J Clin Oncol, 1988, 6, 931-933.
Coiffier B. - How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients? Ann Oncol, 1999, 10, 1141-1143.
Surbone A, Longo DL, DeVita VT, Jr, et al. - Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol, 1988, 6, 1832-1837.
Zinzani PL, Zompatori M, Bendandi M, et al. - Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma, 1996, 22, 131-135.
Hill M, Cunningham D, MacVicar D, et al. - Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol, 1993, 11, 2273-2278.
Israel O, Front D, Lam M, et al. - Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer, 1988, 61, 2439-2443.
Drossman SR, Schiff RG, Kronfeld GD, et al. - Lymphoma of the mediastinum and neck: evaluation with Ga-67 imaging and CT correlation. Radiology, 1990, 174, 171-175.
Zinzani PL, Martelli M, Magagnoli M, et al. - Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood, 1999, 94, 3289-3293.
Front D, Bar-Shalom R, Epelbaum R, et al. - Early detection of lymphoma recurrence with gallium-67 scintigraphy. J Nucl Med, 1993, 34, 2101-2104.
Ben Haim S, Bar-Shalom R, Israel O, et al. - Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma. J Clin Oncol, 1996, 14, 1936-1942.
Front D, Bar-Shalom R, Israel O. - The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging, Semin Nucl Med, 1997, 27, 68-74.
Setoain FJ, Pons F, Herranz R, et al. - 67Ga scintigraphy for the evaluation of recurrences and residual masses in patients with lymphoma. Nucl Med Commun, 1997, 18, 405-411.
Peylan-Ramu N, Haddy TB, Jones E, et al. - High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol, 1989, 7, 1800-1806.
Bar-Shalom R, Israel O, Haim N, et al. - Diffuse lung uptake of Ga-67 after treatment of lymphoma: is it of clinical importance? Radiology, 1996, 199, 473-476.
Newman JS, Francis IR, Kaminski MS, Wahl RL. - Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology, 1994, 190, 111-116.
Moog F, Bangerter M, Diederichs CG et al. Lymphoma: role of whole-body 2-deoxy-2-(F-18)fluoro-D-glucose (FDG) PET in nodal staging. Radiology, 1997, 203, 795-800.
Hoh CK, Glaspy J, Rosen P, et al. - Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med, 1997, 38, 343-348.
Jerusalem G, Warland V, Najjar F, et al. - Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun, 1999, 20, 13-20.
Bangerter M, Moog F, Buchmann I, et al. - Whole-body 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol, 1998, 9, 1117-1122.
Weidmann E, Baican B, Hertel A, et al. - Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymph, 1999, 34, 545-551.
Partridge S, Timothy AR, O'Doherty MJ. - 2-fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretreatement staging of Hodgkin's disease: influence on patient management in a single institution. Ann Oncol, 2000, 11, 1273-1279.
Jerusalem G, Beguin Y, Fassotte MF, et al. - Wholebody positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica, 2001, 86, 266-273.
Jerusalem G, Beguin Y, Najjar F, et al. - Positron emission tomography (PET) with 18F-Fluorodeoxyglucose (18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL). Ann Oncol, 2001, 12, 825-830.
Cremerius U, Fabry U, Neuerburg J, et al. - Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun, 1998, 19, 1055-1063.
Jerusalem G, Beguin Y, Fassotte MF, et al. - Wholebody positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 1999, 94, 429-433.
Zinzani PL, Magagnoli M, Chierichetti F, et al. - The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol, 1999, 10, 1181-1184.
Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. - 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol, 2000, 11, S147-S150.
Maisey NR, Hill ME, Webb A, et al. - Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer, 2000, 36, 200-206.
Spaepen K, Stroobants S, Dupont P, et al. - Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ((18F)FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is (18F)FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol, 2001, 19, 414-419.
de Wit M, Bohuslavizki KH, Buchert R, et al. - 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol, 2001, 12, 29-37.
Jerusalem G, Beguin Y. - Commentary on "Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography". Clin Lymphoma, 2000, 1, 75-76.
Weihrauch MR, Re D, Scheidhauer K, et al. - Thoracic positron emission tomography using (18)F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood, 2001, 98, 2930-2934.
Spaepen K, Stroobants S, Dupont P, et al. - Can positron emission tomography with (18F)-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol, 2001, 115, 272-278.
Hoffmann M, Kletter K, Diemling M, et al. - Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol, 1999, 10, 1185-1189.
